🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“Ask for forgiveness, not for permission” is the name of the game right now. Easier said than done, but the next generation of great scientists are watching and learning from us. Mentors: stay strong & focused - your words & actions matter more than you know.

“There is no better investment than one that saves lives and fuels the economy”

The recent cuts to lifesaving health research are one of many threats that people with cancer face. We stand with blood cancer patients. ❤️ Read more 👉 bit.ly/4gwjExS

Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype ow.ly/PFoV50UZxpl #bloodwork #myeloidneoplasia

Thrilled to share our latest work in nature! We show how cancer cells navigate DNA replication despite DNA damage, revealing new insights into genome stability. Huge thanks to my incredible collaborators! Check it out here: nature.com/articles/s4158…

The Termini Lab is recruiting a Lab Aide to join our group - more information and instructions to apply can be found at the posting below 👇🧫👇🔬👇🐁 careers-fhcrc.icims.com/jobs/29265/lab…

Beyond excited to say my first PhD paper is out today in Cell Stem Cell  📷. Here, we explored the role of epigenetic heterogeneity on malignant expansion, using a new approach called STRACK cell.com/cell-stem-cell…

Exciting Monday for me at Cincinnati Children’s. I had the honor to host one of my mentors Dr. Paulson Vet and Biomedical Sciences at Penn State His talk on “Stress erythropoiesis and pro inflammatory signals” was great! Thank you Cancer and Blood diseases seminar series for this wonderful opportunity!

What protects individuals from developing blood cancers? Thrilled to share my work in Vijay Sankaran lab, describing inherited resilience protecting blood stem cells from clonal hematopoiesis by modifying RNA regulation. 🧵👇(1/n) biorxiv.org/content/10.110…

Linoleic acid is the most abundant polyunsaturated fatty acid in the Western-style diet and has been implicated in promoting inflammation and cancer. In Science, researchers report a mechanism by which linoleic acid can activate the mTORC1 protein kinase, which coordinates

Thrilled to share the first pre-print from our lab! We tackled a big question: Why are some pediatric leukemias extremely aggressive? We explored the developmental origins of fusion-driven acute myeloid leukemia (AML). Let's dive in! #AML #NUP98 n/13

The potency of abnormal genetic fusion in chronic myeloid leukaemia in our latest study nature 👉🏽 nature.com/articles/s4158… This cancer is an oddity - one of the few single genetic “hit” cancers, a short trajectory (few years) from start to diagnosis, and explosive growth.

Age-associated changes in the gut emerge as a #leukemia risk factor. Far-reaching study nature led by cancer experts at Cincinnati Children’s. Findings: nature.com/articles/s4158… Blog: scienceblog.cincinnatichildrens.org/how-bacteria-i…

Save the date!!! Excited to organize version 3 of this fantastic meeting in March 2026 with Fusion Conferences and Samantha Morris & Rahul Satija !!! #singlecell

BCL2 inhibition in adult acute lymphoblastic leukemia (ALL): results of a phase I study combining venetoclax with the CALGB 10403 regimen in newly diagnosed adults with Ph-negative B-cell ALL. haematologica.org/article/view/h…

Thrilled to share our work on the role of taurine in myeloid leukemia progression in @nature today! nature.com/articles/s4158…

My lab's first paper is out in nature. We show that lipoprotein uptake protects tumors from ferroptosis by delivering the lipid antioxidant α-tocopherol. Surprisingly, tumors use sulfated glycosaminoglycans—not canonical receptors—to capture lipoproteins. nature.com/articles/s4158…

Great conversation with the Leukemia Lymphoma Society on Strategies and Advances in AML – Treating Blood Cancers.Listen👇🏾for exciting therapeutic advances for this disease. ⁦The Leukemia & Lymphoma Society⁩ ⁦Leukemia & Lymphoma Society Research⁩ ⁦The James⁩ treatingbloodcancers.org/e104/

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… Congratulations to Dr. Zeidner and BeatAML team. 1. Revumenib was given continuously, dose adjusted for CYP3A4i 2. Ven for 28

Editor sending the friday rejection emails